NCT02279433 - A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions

Solid Tumors

Interventions

DRUG

DS6051b

DS-6051b 50 mg and 200 mg capsules for oral administration

Trial Locations (6)

New York University, New York

South Texas Accelerated Research Therapeutics, San Antonio

HonorHealth Research Institute, Scottsdale

Chao Family Comprehensive Cancer Center of, Orange

Massachusetts General Hospital, Boston

Dana Farber Cancer Inst., Boston